Studies have shown that the mixed covid-19 vaccine is highly effective
“it’s better to be vaccinated with any approved vaccine than not, and two doses of vaccine are better than one dose of vaccine,” said Peter NORDSTR ö m, Professor of geriatrics at umeo University, “However, our study showed that people who received mRNA vaccine after the first dose of vector based vaccine had a greater risk reduction than those who received two doses of vector based vaccine.”
since Oxford AstraZeneca’s vector based vaccine against covid-19 is discontinued for people under the age of 65, all people who have received the first dose of the vaccine are recommended to use mRNA vaccine as their second dose.
mean follow-up of 2.5 months after the second dose During the period, the study showed that compared with non vaccinated people, the combined infection risk of Oxford AstraZeneca + Pfizer biotechnology company was reduced by 67%, while the risk of Oxford / AstraZeneca + Moderna was reduced by 79%. For people who received two doses of Oxford AstraZeneca vaccine, the risk reduction rate was lower, only 50%.
these risk estimates are considering vaccination Observed after differences in date, participant’s age, socio-economic status, and other covid-19 risk factors. Importantly, estimates of effectiveness apply to infection with the delta variant, which dominates confirmed cases during follow-up.
the incidence of adverse thromboembolic events in all vaccine programs is very low. Due to covi serious enough to lead to hospitalization The number of D-19 cases was too small for the researchers to calculate the effectiveness of this result.
previous studies have shown that mixed and matched vaccine programs can produce a strong immune response. However, it is unclear to what extent these programs can reduce the clinical risk Risk of bed infection. This is due to a new study by researchers at the University of Mayo aimed at filling the knowledge gap. The study is based on national registration data from the Swedish public health bureau, the national health and welfare Commission and the Swedish Bureau of statistics. In the main analysis, about 700000 people were included.
“The results of this study may have an impact on vaccination strategies in different countries,” said Marcel Ballin, a doctoral student majoring in geriatrics at umeo University and co-author of the study, “The World Health Organization said that although previous studies have achieved encouraging results in the immune response of mixed and matched vaccines, larger studies are still needed to investigate their safety and effectiveness on clinical results. Here, we now have one such study.”